Do weight loss shots weaken bones? Only 8 small trials checked, review finds

Millions of people now take weight loss shots. Far fewer studies have asked what these medicines do to bones. A new review went looking for every trial that measured bone strength in adults with extra weight who took them. It found just 8, with 493 people in all [1].

In the two trials with the most weight loss, the bones of the hip and lower spine got a little less dense. That means a little less mineral was packed into the bone. In the other trials, the results were mixed [1].

That is a reason to look closer, not proof of harm. The trials were small, and not one of them counted broken bones [1].

The review was led by Cheng-Hao Lai of Chung Shan Medical University in Taichung, Taiwan. It was published in Archives of Osteoporosis in October 2026. The paper's public record does not list a funder [1].

Why look at bones at all?

These medicines act like GLP-1, a hormone the gut releases after a meal. The review covered four of them: exenatide, liraglutide, dulaglutide and semaglutide [1].

Bone is living tissue that is always being broken down and rebuilt. Its strength is measured with a gentle X-ray scan called DXA. The scan reports bone mineral density, a measure of how much mineral is packed into the bone. Losing weight by any means tends to bring some bone loss with it, which is one reason scientists want to check these medicines [1][2].

What did the review find?

Most of the evidence was thin. Exenatide had five trials, liraglutide two, and dulaglutide and semaglutide one each, with one trial testing two medicines. Five of the eight trials were in people with type 2 diabetes, a disease where blood sugar runs too high, rather than in people with obesity alone. The medicines also differ a lot in how much weight they take off. So the authors did not pool the trials into one number, and reported each medicine on its own [1].

The semaglutide trial was led by Morten Hansen in Denmark. It gave 64 adults at higher risk of broken bones a weekly shot of the medicine or a fake shot for a year. Most were women past menopause, with an average age of 63. People on the medicine lost about 6.8 kilograms more than people on the fake shot [3].

That trial's main question was whether the medicine helps the body build new bone, read from a blood marker called PINP. It did not. Its other measures were less kind. Lower spine and hip bones ended up slightly less dense on the medicine, and a blood marker of bone being broken down went up [3].

The trial was funded by the Region of Southern Denmark, the Novo Nordisk Foundation and the Gangsted Foundation. Novo Nordisk, which makes semaglutide, supplied the medicine and the fake shots [3].

The liraglutide trial was led by Simon Birk Kjær Jensen at the University of Copenhagen. It put 195 adults with obesity on a very low calorie diet for 8 weeks. Then each got a year of exercise, the medicine, both, or a fake shot. People on the medicine alone lost more hip and spine bone than people who only exercised, even though their weight loss was similar. By contrast, people who did both kept their bone about level with the fake shot group [2].

A different liraglutide trial used the lower amount given for diabetes, and weight loss was smaller. There, no bone site changed in any real way [1]. The authors summed up the whole picture this way:

The randomized evidence is too sparse and too clinically heterogeneous to determine the skeletal effects of GLP-1 RA therapy in adults with overweight or obesity.

Lai and colleagues, Archives of Osteoporosis, 2026 [1]

In plain words, there are too few trials, and they are too unlike each other, to say what these medicines do to bones. The authors rated the certainty of the evidence as very low for every medicine [1].

What does the review not show?

It does not show that these medicines cause broken bones. Bone density is a marker, a number that hints at the risk of a break, and no trial in the review counted actual fractures. The authors call for larger trials of each medicine that count breaks [1].

The review's plan was posted in March 2026 on a public registry of review plans called INPLASY, under the number INPLASY202630076. That registry record calls it a systematic review and meta-analysis, which means a search for every trial plus pooling them into one result. The published paper did no pooling, and it explains why: the medicines differ too much to add together [1][4].

Another review read a much wider pile of evidence. Led by Charlotte Beaudart of the University of Namur in Belgium and published in Drugs in 2026, it took in 60 studies, including large sets of health records. When it pooled them, it found no effect of these medicines on bone density or fractures. It did find a loss of lean mass, the weight of everything in the body except fat, such as muscle [5].

So two reviews read the same field differently, one by pooling and one by refusing to. Neither settles whether people taking these shots for weight loss break more bones. The first review says that answer needs bigger trials, built for each medicine, that count fractures [1][5].